MicroRNA-372 is associated with poor prognosis in colorectal cancer

Shinya Yamashita, Hirofumi Yamamoto, Koshi Mimori, Naohiro Nishida, Hidekazu Takahashi, Naotsugu Haraguchi, Fumiaki Tanaka, Kohei Shibata, Mitsugu Sekimoto, Hideshi Ishii, Yuichiro Doki, Masaki Mori

Research output: Contribution to journalArticlepeer-review

52 Citations (Scopus)

Abstract

Objective: MicroRNA-372 (miR-372) is reportedly shown to be an oncogene in human testicular germ cell tumors and gastric cancers, but its expression in colorectal cancer (CRC) is not yet determined. This study investigated the clinical significance of miR-372 expression in CRC. Methods: qRT-PCR was used to evaluate miR-372 in 144 CRC patients, and large tumor suppressor 2 (LATS2) expression was also examined as the likely target gene of miR-372 . In vitro assays were performed to evaluate the biological function of miR-372. Results: Multivariate analysis indicated that high miR-372 expression was an independent prognostic factor (p = 0.006). High miR-372 expression was associated with synchronous liver metastasis (p = 0.035). We found an inverse relationship between miR-372 and LATS2 by qRT-PCR (p = 0.007) and immunohistochemistry (p = 0.042) using CRC tissue samples. Furthermore, pre-miR-372 led to a decrease in the LATS2 protein and an increase in proliferative activity of LoVo cells. We also found a significant association between low LATS2 expression and liver metastasis (p = 0.042). Conclusions: This study suggested that miR-372 was a novel independent prognostic factor in CRC. Our data suggest that LATS2 may serve as one of the target genes of miR-372 in clinical CRC tissues. Copyright 7copy; 2012 S. Karger AG, Basel.

Original languageEnglish
Pages (from-to)205-212
Number of pages8
JournalOncology
Volume82
Issue number4
DOIs
Publication statusPublished - Apr 2012

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'MicroRNA-372 is associated with poor prognosis in colorectal cancer'. Together they form a unique fingerprint.

Cite this